The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic patients with portal vein thrombosis and to explore whether it can decrease the short-term rebleeding rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Calcium; Calcium, Dietary; Nadroparin; Warfarin

Criteria

Inclusion Criteria:

• Age between 18-70 years old;

• A clinical, radiological or histologic diagnosis of Liver cirrhosis and portal hypertension;

• Diagnosed of Portal vein thrombosis;

• Capable of understanding the purpose and risks of the study and informed consent to participate in the study;

• Have undergone endoscopy to prevent variceal rebleeding.

Exclusion Criteria:

• Age <18 or >70 years;

• Portal vein thrombosis diagnosed before 6 months;

• Patients with signs of acute PVT such as fever，abdominal pain or intestinal obstruction，who should be treated immediately;

• Pregnant or nursing;

• Hepatocellular carcinoma;

• Severe cardiopulmonary diseases or concomitant renal insufficiency;

• cavernous transformation of the portal vein;

• Contradictions to endoscopy;

• Contradictions to anticoagulation,such as:allergy to LMWH or warfarin, severe uncontrolled hypertension, history of hemorrhagic cerebral vascular accident, recent peptic ulcer disease, bacterial endocarditis, ulcerative colitis，sustained platelet count < 50 x103/uL);

• Taking immunosuppressive agent;

• Coagulation disorders other than the liver disease related;

• Variceal bleeding failed to control.